Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Volume 22 - Issue 1 - January, 2010

Insights

Commentary
Measuring the Right Compound at the Right Time is Not Always Easy
01/07/2010
Sorin J. Brener, MD
Sorin J. Brener, MD
The introduction of intravenous glycoprotein IIb/IIIa inhibitors (GPI) nearly two decades ago has revolutionized the care of patients undergoing percutaneous coronary intervention (PCI). Enrollment in GPI trials was the fastest ever reported...
The introduction of intravenous glycoprotein IIb/IIIa inhibitors (GPI) nearly two decades ago has revolutionized the care of patients undergoing percutaneous coronary intervention (PCI). Enrollment in GPI trials was the fastest ever reported...
The introduction of intravenous...
01/07/2010
Journal of Invasive Cardiology
Commentary
Three Years Since the FDA Advisory Panel on Drug-Eluting Stents: What Have We Learned about Off-Label Use and Stent Thrombosis?
01/07/2010
Srihari S. Naidu, MD
Srihari S. Naidu, MD
The arrival of drug-eluting stents in interventional cardiovascular practice heralded a new era in the management of patients with symptomatic coronary artery disease. Indeed, while bare metal stents were a clear technological breakthrough,...
The arrival of drug-eluting stents in interventional cardiovascular practice heralded a new era in the management of patients with symptomatic coronary artery disease. Indeed, while bare metal stents were a clear technological breakthrough,...
The arrival of drug-eluting...
01/07/2010
Journal of Invasive Cardiology

Feature

Original Contribution
A Poly-N-acetyl Glucosamine Hemostatic Dressing for Femoral Artery Access Site Hemostasis after Percutaneous Coronary Intervention: A Pilot Study
01/07/2010

David Mego, MD, Melody Thomas, LPN, Jeff Stewart, MD, William Rollefson, MD, Patrick Flaherty, DO, Bruce Murphy, MD, PhD, Paul Ribeiro, MD

 

Arkansas Heart Hospital, Little Rock, Arkansas

David Mego, MD, Melody Thomas, LPN, J...
Arterial puncture closure devices have improved time to hemostasis and ambulation after percutaneous coronary intervention (PCI) relative to traditional manual compression, though complication rates for both methods leave room for...
Arterial puncture closure devices have improved time to hemostasis and ambulation after percutaneous coronary intervention (PCI) relative to traditional manual compression, though complication rates for both methods leave room for...
Arterial puncture closure...
01/07/2010
Journal of Invasive Cardiology
Original Contribution
Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation
01/07/2010
Cynthia A. Yock, MS*, J. Michael Isbill, MS§, Spencer B. King III£, MD, Mark A. Hlatky, MD*
Cynthia A. Yock, MS*, J. Michael Isbi...
ABSTRACT: Background. The goal of this study was to assess the rate and anatomical targets of repeat revascularization procedures in routine clinical practice after either bare-metal stent (BMS) or drug-eluting stent (DES) implantation....
ABSTRACT: Background. The goal of this study was to assess the rate and anatomical targets of repeat revascularization procedures in routine clinical practice after either bare-metal stent (BMS) or drug-eluting stent (DES) implantation....
ABSTRACT: Background. The goal...
01/07/2010
Journal of Invasive Cardiology
Original Contribution
How Much Alcohol Should We Infuse in the Coronary Artery of Hypertrophic Cardiomyopathy Patients?
01/07/2010
Raed Aqel, MD*, Fadi G Hage, MD*, Wael AlJaroudi, MD, David Lawson, PA, Aaron Sweeney, MD, Sachin Hansalia, MD, Koteswara Pothineni, MD, Jaekyeong Heo, MD, Octavio Pajaro, MD, David McGiffin, MD, Louis Dell'Italia, MD, Ami E Iskandrian, MD
Raed Aqel, MD*, Fadi G Hage, MD*, Wae...
ABSTRACT: Background. Although alcohol septal ablation (ASA) is increasingly used in hypertrophic cardiomyopathy (HC) patients who are refractory to medical therapy, the amount of alcohol that is required has not been well studied. This study...
ABSTRACT: Background. Although alcohol septal ablation (ASA) is increasingly used in hypertrophic cardiomyopathy (HC) patients who are refractory to medical therapy, the amount of alcohol that is required has not been well studied. This study...
ABSTRACT: Background. Although...
01/07/2010
Journal of Invasive Cardiology
Original Contribution
Association Between Off-Label Use of Drug-Eluting Stents and Subsequent Stent Thrombosis: A Case-Control Analysis
01/07/2010
Asaf Rabinovitz, MD*, Dara M. Bier, BS§, Gabriel M. Wagman, MD*, Esti Charlap, BA§, Reza Nazari, MD, Jaime Ghitelman, MD£, Sulejman Celaj, MD£, Basel Skeif, MD£, Mark Menegus, MD£, V. S. Srinivas, MBBS£
Asaf Rabinovitz, MD*, Dara M. Bier, ...
ABSTRACT: Objectives. We sought to examine the association between off-label drug-eluting stent (DES) use and stent thrombosis (ST) in unselected patients undergoing percutaneous coronary intervention (PCI). Background. DES are frequently...
ABSTRACT: Objectives. We sought to examine the association between off-label drug-eluting stent (DES) use and stent thrombosis (ST) in unselected patients undergoing percutaneous coronary intervention (PCI). Background. DES are frequently...
ABSTRACT: Objectives. We sought...
01/07/2010
Journal of Invasive Cardiology
Original Contribution
Increased Vascular Access Complications in Patients with Renal Dysfunction (Full title below)
01/07/2010
Emad F. Aziz, MB, ChB, DOa, Sandeep Pulimi, MDa, Clinton Coleman, MDb, Calatin Florita, MDc, Dan Musat, MDa, Deborah Tormey, RNa, Ashraf Fawzy, BSa, Steve Lee, BSa, Eyal Herzog, MDa, David L. Coven, MDa, Jacqueline Tamis-Holland, MDa, Mun K. Hong, MDa
Emad F. Aziz, MB, ChB, DOa, Sandeep ...
Increased Vascular Access Complications in Patients with Renal Dysfunction Undergoing Percutaneous Coronary Procedures Using Arteriotomy Closure Devices ABSTRACT: Background. Arteriotomy closure device (ACD) use has increased following...
Increased Vascular Access Complications in Patients with Renal Dysfunction Undergoing Percutaneous Coronary Procedures Using Arteriotomy Closure Devices ABSTRACT: Background. Arteriotomy closure device (ACD) use has increased following...
Increased Vascular Access...
01/07/2010
Journal of Invasive Cardiology
Original Contribution
The Relative Effects of Abciximab and Tirofiban on Platelet Inhibition and C-Reactive Protein during Coronary Intervention
01/07/2010
Adam J. Saltzman, MD, Roxana Mehran, MD, W. Craig Hooper, PhD*, Jeffrey W. Moses, MD, Giora Weisz, MD, Michael B. Collins, MD, Alexandra J. Lansky, MD, Edward M. Kreps, MD, Martin B. Leon, MD, Gregg W. Stone, MD, George Dangas, MD
Adam J. Saltzman, MD, Roxana Mehran,...
ABSTRACT: Background. We sought to compare the efficacy of tirofiban and abciximab on platelet inhibition as well as their effects of platelet inhibition on C-reactive protein levels during percutaneous coronary intervention (PCI). Methods....
ABSTRACT: Background. We sought to compare the efficacy of tirofiban and abciximab on platelet inhibition as well as their effects of platelet inhibition on C-reactive protein levels during percutaneous coronary intervention (PCI). Methods....
ABSTRACT: Background. We sought...
01/07/2010
Journal of Invasive Cardiology

Advertisement

Advertisement

Advertisement

News

A study led by researchers from Shinshu University propose a simplified risk-scoring model helps clinicians assess when patients with cardiogenic shock can be safely weaned off from MCS devices, such as VA-ECMO or IMPELLA, using easily measurable health indicators like blood pressure and heart function. Credit Sho Suzuki from Shinshu University
Mechanical Circulatory Support
A Simple Risk Score for Weaning Patients From Mechanical Circulatory Support
10/23/2024
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Researchers from Shinshu...
10/23/2024
Cath Lab Digest
The initial cases with the Luna TMVR System were conducted in Paraguay and the Republic of Georgia and supported by leading US structural heart experts and the Tioga Cardiovascular team.
Mitral Valve intervention
Tioga Cardiovascular Announces First-In-Human Cases With Its Luna Transcatheter Mitral Valve Replacement (TMVR) System
10/23/2024
Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced the first-in-human transseptal implantations using the 28 French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved excellent...
Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced the first-in-human transseptal implantations using the 28 French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved excellent...
Tioga Cardiovascular, Inc., a...
10/23/2024
Cath Lab Digest
CABG
Black Patients More Likely to Die After Coronary Bypass Surgery
10/22/2024
Compared to white patients, Black patients were 22% more likely to die in the hospital. Black patients stayed in the hospital 1.5 days longer on average (9.6 days for white patients, 10.7 days for Hispanic patients and 11.8 days for Black...
Compared to white patients, Black patients were 22% more likely to die in the hospital. Black patients stayed in the hospital 1.5 days longer on average (9.6 days for white patients, 10.7 days for Hispanic patients and 11.8 days for Black...
Compared to white patients,...
10/22/2024
Cath Lab Digest
Medaxiom survey
Cardiology Compensation and Production Reflect Post-Pandemic Changes to Provider Market
10/21/2024
MedAxiom News NEPTUNE BEACH, Fla. – MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2024 Cardiovascular Provider Compensation and Production Survey Report that includes data from the...
MedAxiom News NEPTUNE BEACH, Fla. – MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2024 Cardiovascular Provider Compensation and Production Survey Report that includes data from the...
MedAxiom News NEPTUNE BEACH,...
10/21/2024
Cath Lab Digest
Cardiology Innovations
Philips Showcases Next Level Cardiology Innovations for Improved Patient Care at TCT 2024
10/21/2024
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment...
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment...
Philips portfolio of...
10/21/2024
Vascular Disease Management
Cardiovascular Risk After MI
Prolocor Announces Publication of Confirmatory Results From Multicenter 800 Patient Study in the Journal of the American College of Cardiology (JACC)
10/21/2024
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death  Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome...
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death  Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome...
Greater than 2-fold...
10/21/2024
Vascular Disease Management
Pharmaceuticals
Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction
10/21/2024
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg...
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg...
The LIBERATE phase 2b,...
10/21/2024
Cath Lab Digest
PVD
Yale Study Finds Link Between Eczema and Peripheral Vascular Disease
10/21/2024
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
The Yale team found PVD occurred...
10/21/2024
Cath Lab Digest
plaque analysis
HeartFlow Announces New Category I CPT Code from the American Medical Association for AI-Enabled Plaque Analysis to Assess Risk for Coronary Artery Disease
10/18/2024
“We commend the AMA’s issuance of this upgraded Category I CPT billing code, which validates the technology’s clinical value in quantifying and characterizing plaque to help assess risk and personalize treatment for patients with coronary...
“We commend the AMA’s issuance of this upgraded Category I CPT billing code, which validates the technology’s clinical value in quantifying and characterizing plaque to help assess risk and personalize treatment for patients with coronary...
“We commend the AMA’s issuance...
10/18/2024
Cath Lab Digest
Hypertension
New Study Links Obesity to Elevated Hypertension Risk Among Young Middle Eastern Women
10/18/2024
“Young Middle Eastern women who are obese or overweight are facing a higher risk for the development of atherosclerotic cardiovascular disease and its associated risk factors like hypertension and Type Two diabetes,” said Mohammad Adnan Bani...
“Young Middle Eastern women who are obese or overweight are facing a higher risk for the development of atherosclerotic cardiovascular disease and its associated risk factors like hypertension and Type Two diabetes,” said Mohammad Adnan Bani...
“Young Middle Eastern women who...
10/18/2024
Cath Lab Digest

Advertisement

Advertisement

A study led by researchers from Shinshu University propose a simplified risk-scoring model helps clinicians assess when patients with cardiogenic shock can be safely weaned off from MCS devices, such as VA-ECMO or IMPELLA, using easily measurable health indicators like blood pressure and heart function. Credit Sho Suzuki from Shinshu University
Mechanical Circulatory Support
A Simple Risk Score for Weaning Patients From Mechanical Circulatory Support
10/23/2024
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Researchers from Shinshu...
10/23/2024
Cath Lab Digest
Original Contribution
Intravascular Ultrasound in the Assessment of Coronary Artery Anomalies in Young Patients: A Tertiary Center Experience
10/23/2024
The authors describe a young population of patients with anomalous aortic origin of a coronary artery and myocardial bridge and review the safety of intravascular ultrasound in this population.
The authors describe a young population of patients with anomalous aortic origin of a coronary artery and myocardial bridge and review the safety of intravascular ultrasound in this population.
The authors describe a young...
10/23/2024
Journal of Invasive Cardiology
The initial cases with the Luna TMVR System were conducted in Paraguay and the Republic of Georgia and supported by leading US structural heart experts and the Tioga Cardiovascular team.
Mitral Valve intervention
Tioga Cardiovascular Announces First-In-Human Cases With Its Luna Transcatheter Mitral Valve Replacement (TMVR) System
10/23/2024
Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced the first-in-human transseptal implantations using the 28 French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved excellent...
Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced the first-in-human transseptal implantations using the 28 French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved excellent...
Tioga Cardiovascular, Inc., a...
10/23/2024
Cath Lab Digest
Original Contribution
Comparison of Two Vascular Closure Device Strategies for Transfemoral Transcatheter Aortic Valve Replacement Using Suture-Based and Collagen-Plug-Based Techniques and Associated Vascular Complications
10/23/2024
The authors evaluated their experience with 2 distinct vascular closure device approaches using the Perclose ProGlide and the Angio-Seal, as well as the impact on vascular access site complications during transcatheter aortic valve...
The authors evaluated their experience with 2 distinct vascular closure device approaches using the Perclose ProGlide and the Angio-Seal, as well as the impact on vascular access site complications during transcatheter aortic valve...
The authors evaluated their...
10/23/2024
Journal of Invasive Cardiology
CABG
Black Patients More Likely to Die After Coronary Bypass Surgery
10/22/2024
Compared to white patients, Black patients were 22% more likely to die in the hospital. Black patients stayed in the hospital 1.5 days longer on average (9.6 days for white patients, 10.7 days for Hispanic patients and 11.8 days for Black...
Compared to white patients, Black patients were 22% more likely to die in the hospital. Black patients stayed in the hospital 1.5 days longer on average (9.6 days for white patients, 10.7 days for Hispanic patients and 11.8 days for Black...
Compared to white patients,...
10/22/2024
Cath Lab Digest
Medaxiom survey
Cardiology Compensation and Production Reflect Post-Pandemic Changes to Provider Market
10/21/2024
MedAxiom News NEPTUNE BEACH, Fla. – MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2024 Cardiovascular Provider Compensation and Production Survey Report that includes data from the...
MedAxiom News NEPTUNE BEACH, Fla. – MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 2024 Cardiovascular Provider Compensation and Production Survey Report that includes data from the...
MedAxiom News NEPTUNE BEACH,...
10/21/2024
Cath Lab Digest
Cardiology Innovations
Philips Showcases Next Level Cardiology Innovations for Improved Patient Care at TCT 2024
10/21/2024
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment...
Philips portfolio of image-guided therapy and echocardiography solutions uniquely integrates artificial intelligence into imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment...
Philips portfolio of...
10/21/2024
Vascular Disease Management
Cardiovascular Risk After MI
Prolocor Announces Publication of Confirmatory Results From Multicenter 800 Patient Study in the Journal of the American College of Cardiology (JACC)
10/21/2024
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death  Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome...
Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death  Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome...
Greater than 2-fold...
10/21/2024
Vascular Disease Management
Pharmaceuticals
Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction
10/21/2024
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg...
The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from STEMI who are scheduled to undergo PCI. The study’s primary objective is to assess the safety and efficacy of glenzocimab 1000 mg...
The LIBERATE phase 2b,...
10/21/2024
Cath Lab Digest
PVD
Yale Study Finds Link Between Eczema and Peripheral Vascular Disease
10/21/2024
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
The Yale team found PVD occurred in 11% of patients with atopic dermatitis (AD), but just 6.2% of patients without AD.
The Yale team found PVD occurred...
10/21/2024
Cath Lab Digest

January 2010 Volume 22 Issue 1

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement